FDA Safety Flag Not a Protocol
FDA · TGA · WADA · peer-reviewed literature Updated May 2026 Reviewed by Allmeds AI Pharmacist

Ipamorelin Dosage: Why No Safe Human Dose Has Been Established

Ipamorelin is a selective ghrelin-receptor agonist marketed for GH-axis stimulation. It is not FDA-approved, and the FDA has explicitly identified ipamorelin acetate among compounded substances that may present significant safety risks. No controlled human trial has established a safe and effective dose for the marketed uses. This page does not publish a protocol.

The FDA has flagged ipamorelin acetate for significant safety concerns when compounded. No regulator-validated human dose exists for marketed anti-aging or body-composition use. Online protocols are derived from preclinical or anecdotal sources, not from controlled human trials. WADA prohibits ipamorelin in competitive sport.

Key Takeaways

  • Ipamorelin is not FDA-approved for any marketed use.
  • The FDA has identified ipamorelin acetate among compounded substances that may present significant safety risks.
  • No regulator-validated human dose has been established.
  • WADA prohibits ipamorelin in competitive sport.
  • Allmeds does not publish dosing protocols for FDA-flagged compounded peptides.

FDA position on ipamorelin

The FDA has identified ipamorelin acetate among compounded substances that may present significant safety risks. The position cites potential immunogenicity, peptide impurity, API characterisation complexity, and limited safety information. This is the most consequential regulator statement to consider before any planned use.

Why no human dose is established

Ipamorelin has not been approved by the FDA, EMA, or TGA for any therapeutic indication. No adequately controlled human trial has established a safe and effective dose for the marketed anti-aging or body-composition uses. Online protocols are derived from preclinical work and anecdotal community practice.

Check your medications before any change

Allmeds scans interactions across your full list. Free for individuals; team plans available.

Try it free → Talk to Sales

Common Questions

Is there an FDA-approved ipamorelin dose?

No. Ipamorelin is not FDA-approved. The FDA has explicitly listed ipamorelin acetate among compounded substances that may present significant safety risks.

Why don't you publish an ipamorelin protocol?

Because the FDA has flagged the substance for significant safety concerns and no regulator-validated dose exists. Publishing a protocol would imply a safety floor that has not been demonstrated.

Is ipamorelin banned in sport?

Yes. WADA prohibits ipamorelin.

What should I do if I am considering ipamorelin?

Discuss the FDA position, the absence of regulator-validated dosing, and the specific concerns with non-pharmaceutical injected peptide with a qualified clinician.

References

  1. U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Source.
  2. World Anti-Doping Agency. WADA Prohibited List. Source.
  3. Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). Source.
Not medical advice. This page summarises regulator statements and peer-reviewed literature for general information. It is not a substitute for professional medical advice. Speak to your doctor or pharmacist before starting, stopping, or changing any medicine.